Is Moderna on Track to Win Authorization for Its Vaccine in Younger Kids?
Moderna (NASDAQ: MRNA) recently announced positive results from a clinical study of its COVID-19 vaccine in children ages 6 to 11. However, since then, the company has pushed back its filing for Emergency Use Authorization (EUA) in this age group because the U.S. Food and Drug Administration (FDA) extended its review of the company's data for adolescents. In this Motley Fool Live video recorded on Oct. 27, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether Moderna is on track to win authorization for its vaccine in younger kids.
Source Fool.com
